On Friday, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ: YMAB) did not provide sufficient evidence to conclude that omburtamab improves over...
On Friday, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ: YMAB) did not provide sufficient evidence to conclude that omburtamab improves over...